These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25895921)

  • 21. PD-1 Blockers.
    Wolchok JD
    Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spotlight on pembrolizumab in the treatment of advanced melanoma.
    Rajakulendran T; Adam DN
    Drug Des Devel Ther; 2015; 9():2883-6. PubMed ID: 26082618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
    Maul LV; Weichenthal M; Kähler KC; Hauschild A
    J Immunother; 2016 May; 39(4):188-90. PubMed ID: 27023060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ipilimumab: from preclinical development to future clinical perspectives in melanoma.
    Letendre P; Monga V; Milhem M; Zakharia Y
    Future Oncol; 2017 Mar; 13(7):625-636. PubMed ID: 27882779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining immune checkpoint inhibitors for advanced melanoma: the key to optimizing treatment outcomes?
    Freeston S
    J Comp Eff Res; 2016 Jul; 5(4):329-33. PubMed ID: 27331424
    [No Abstract]   [Full Text] [Related]  

  • 26. The proportion of circulating CD45RO
    Tietze JK; Angelova D; Heppt MV; Reinholz M; Murphy WJ; Spannagl M; Ruzicka T; Berking C
    Eur J Cancer; 2017 Apr; 75():268-279. PubMed ID: 28242504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NICE guidance on pembrolizumab for advanced melanoma.
    Watson I; Dominguez PP; Donegan E; Charles Z; Robertson J; Adam EJ
    Lancet Oncol; 2016 Jan; 17(1):21-2. PubMed ID: 26621380
    [No Abstract]   [Full Text] [Related]  

  • 28. [Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies].
    Robert C; Mateus C
    Bull Acad Natl Med; 2014 Feb; 198(2):297-308. PubMed ID: 26263705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ipilimumab: in previously treated patients with advanced melanoma.
    Sanford M
    BioDrugs; 2012 Jun; 26(3):185-93. PubMed ID: 22530681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Checkpoint inhibitors-indications and application in melanoma patients].
    Lamos C; Hunger RE
    Z Rheumatol; 2020 Oct; 79(8):818-825. PubMed ID: 32926216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pembrolizumab for the treatment of melanoma.
    Kumar SS; McNeil CM
    Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
    Hua C; Boussemart L; Mateus C; Routier E; Boutros C; Cazenave H; Viollet R; Thomas M; Roy S; Benannoune N; Tomasic G; Soria JC; Champiat S; Texier M; Lanoy E; Robert C
    JAMA Dermatol; 2016 Jan; 152(1):45-51. PubMed ID: 26501224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.
    Gangadhar TC; Hwu WJ; Postow MA; Hamid O; Daud A; Dronca R; Joseph R; O'Day SJ; Hodi FS; Pavlick AC; Kluger H; Oxborough RP; Yang A; Gazdoiu M; Kush DA; Ebbinghaus S; Salama AKS
    J Immunother; 2017; 40(9):334-340. PubMed ID: 29028788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ipilimumab: showing survival benefit in metastatic melanoma.
    Minchom A; Young K; Larkin J
    Future Oncol; 2011 Nov; 7(11):1255-64. PubMed ID: 22044200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ipilimumab lesson in melanoma: achieving long-term survival.
    Delyon J; Maio M; Lebbé C
    Semin Oncol; 2015 Jun; 42(3):387-401. PubMed ID: 25965357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pembrolizumab: first global approval.
    Poole RM
    Drugs; 2014 Oct; 74(16):1973-1981. PubMed ID: 25331768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scleroderma Induced by Pembrolizumab: A Case Series.
    Barbosa NS; Wetter DA; Wieland CN; Shenoy NK; Markovic SN; Thanarajasingam U
    Mayo Clin Proc; 2017 Jul; 92(7):1158-1163. PubMed ID: 28599746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
    Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR
    J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018.
    Board R; Smittenaar R; Lawton S; Liu H; Juwa B; Chao D; Corrie P
    Int J Cancer; 2021 Feb; 148(4):868-875. PubMed ID: 32838478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.